Acrodermatitis chronica atrophicans medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Raviteja Guddeti, M.B.B.S. [3]
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans medical therapy On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans medical therapy |
|
Acrodermatitis chronica atrophicans medical therapy in the news |
|
Blogs on Acrodermatitis chronica atrophicans medical therapy |
|
Risk calculators and risk factors for Acrodermatitis chronica atrophicans medical therapy |
Overview
Treatment of acrodermatitis chronica atrophicans consists of antibiotics such as doxycycline and penicillin. The recommended duration for treatment is up to four weeks in acute cases.
Medical Therapy
- Antibiotic therapy is recommended in patients with acrodermatitis chronica atrophicans.[1]
- Up to four weeks treatment with antibiotics such as doxycycline and penicillin has been recommended in acute cases.[2]
- 92% of patients in a study had significant reduction in level of antibody after proper antibiotic therapy.[3]
- In vitro investigations have been revealed borrelia susceptibility to antibiotics such as erythromycin, ceftriaxone and cefotaxime. Except for erythromycin, borrelia showed susceptibility to ceftriaxone and cefotaxime also in in vivo evaluations. [4]
References
- ↑ Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B; et al. (1988). "Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans". Ann N Y Acad Sci. 539: 324–45. doi:10.1111/j.1749-6632.1988.tb31867.x. PMID 3056202.
- ↑ Aberer, Elisabeth; Breier, F.; Stanek, G.; Schmidt, B. (1996). "Success and failure in the treatment of acrodermatitis chronica atrophicans". Infection. 24 (1): 85–87. doi:10.1007/BF01780666. ISSN 0300-8126.
- ↑ . doi:10.2340/0001555574424428. Missing or empty
|title=(help) - ↑ Mursic, V. P.; Wilske, B.; Schierz, G.; Holmburger, M.; Süß, E. (1987). "In vitro and in vivo susceptibility ofBorrelia burgdorferi". European Journal of Clinical Microbiology. 6 (4): 424–426. doi:10.1007/BF02013102. ISSN 0722-2211.